Pfizer Inc. and its lawyers at White & Case fended off a major challenge from generic rivals on Thursday, persuading an appeals court that patents for the painkiller Lyrica give the company exclusive rights to sell the drug through the end of 2018.
A group of eight drugmakers had sought to make their own versions of the pain and antiseizure medication, which generated $3.7 billion in revenue for Pfizer in 2011. But the U.S. Court of Appeals for the Federal Circuit upheld a lower court ruling that patents are valid and infringed by the proposed copycat drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
